[go: up one dir, main page]

CO6491040A2 - 5-fenil-(1,2,4) triazolo (1,5-a) piridin - 2 il carboxamida como inhibidor de jak - Google Patents

5-fenil-(1,2,4) triazolo (1,5-a) piridin - 2 il carboxamida como inhibidor de jak

Info

Publication number
CO6491040A2
CO6491040A2 CO12005379A CO12005379A CO6491040A2 CO 6491040 A2 CO6491040 A2 CO 6491040A2 CO 12005379 A CO12005379 A CO 12005379A CO 12005379 A CO12005379 A CO 12005379A CO 6491040 A2 CO6491040 A2 CO 6491040A2
Authority
CO
Colombia
Prior art keywords
diseases
piridin
triazolo
carboxamide
phenyl
Prior art date
Application number
CO12005379A
Other languages
English (en)
Inventor
Christel Jeanne Marie Menet
Koen Kurt Smits
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6491040(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CO6491040A2 publication Critical patent/CO6491040A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revela un nuevo compuesto capaz de inhibir JAK; este compuesto puede prepararse como una composición farmacéutica, y puede usarse para la prevención y el tratamiento de una diversidad de afecciones en mamíferos, que incluyen humanos, que abarcan, a modo de ejemplo, sin limitación, afecciones inflamatorias, enfermedades auto inmunitarias, enfermedades proliferativas, rechazo de trasplantes, enfermedades que involucran el deterioro del recambio de cartílago, malformaciones congénitas del cartílago y enfermedades asociadas con la hipersecreción de IL6.
CO12005379A 2009-06-26 2012-01-16 5-fenil-(1,2,4) triazolo (1,5-a) piridin - 2 il carboxamida como inhibidor de jak CO6491040A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22068809P 2009-06-26 2009-06-26

Publications (1)

Publication Number Publication Date
CO6491040A2 true CO6491040A2 (es) 2012-07-31

Family

ID=42562363

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12005379A CO6491040A2 (es) 2009-06-26 2012-01-16 5-fenil-(1,2,4) triazolo (1,5-a) piridin - 2 il carboxamida como inhibidor de jak

Country Status (43)

Country Link
US (9) US8088764B2 (es)
EP (2) EP3178819B1 (es)
JP (2) JP5591925B2 (es)
KR (3) KR101916194B1 (es)
CN (2) CN102482273B (es)
AR (1) AR077220A1 (es)
AU (3) AU2010264633B2 (es)
BR (1) BRPI1015569B8 (es)
CA (1) CA2765985C (es)
CL (1) CL2011003247A1 (es)
CO (1) CO6491040A2 (es)
CR (1) CR20120016A (es)
CY (3) CY1119214T1 (es)
DK (2) DK3178819T3 (es)
DO (1) DOP2011000388A (es)
EA (1) EA021637B1 (es)
EC (1) ECSP12011626A (es)
ES (2) ES2626908T3 (es)
FR (1) FR21C1011I2 (es)
GB (1) GB2483424B (es)
HR (2) HRP20170826T1 (es)
HU (3) HUE047478T2 (es)
IL (1) IL216667A (es)
LT (3) LT3178819T (es)
MA (1) MA33448B1 (es)
ME (1) ME02699B (es)
MX (1) MX344951B (es)
MY (1) MY156664A (es)
NI (1) NI201100222A (es)
NL (1) NL301096I2 (es)
NO (1) NO2021013I1 (es)
NZ (1) NZ596838A (es)
PE (1) PE20121032A1 (es)
PL (2) PL2445911T3 (es)
PT (2) PT3178819T (es)
RS (1) RS56035B1 (es)
SG (2) SG177363A1 (es)
SI (2) SI2445911T1 (es)
SM (1) SMT201700265T1 (es)
TW (1) TWI462920B (es)
UA (1) UA107935C2 (es)
WO (1) WO2010149769A1 (es)
ZA (1) ZA201109386B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
AR086042A1 (es) * 2011-04-28 2013-11-13 Galapagos Nv Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
JP2014532654A (ja) * 2011-10-26 2014-12-08 シュタイン, エミリー, エイ.STEIN, Emily, A. 神経機能に影響を及ぼす薬剤、方法、およびデバイス
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
UY34855A (es) 2012-06-22 2014-01-31 Galapagos Nv Aminotriazolopiridina para usar el tratamiento de la inflamación y composiciones farmacéuticas de ella.
GB201302036D0 (en) * 2013-02-05 2013-03-20 Queen Mary & Westfield College Diagnosis
MX2016007494A (es) * 2013-12-11 2016-10-03 Cephalon Inc Tratamiento de la esclerosis multiple con un derivado de 1,2,4-triazolo [1,5-a] piridina.
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh) 2014-09-02 2019-12-11 日商日本新藥股份有限公司 吡唑并噻唑化合物及醫藥
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
WO2016165952A1 (en) 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of cardiovascular disorders
WO2016165953A1 (en) 2015-04-13 2016-10-20 Galapagos Nv Methods for the treatment of inflammatory disorders
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) * 2015-07-14 2017-01-11 苏州富士莱医药股份有限公司 一种Filgotinib的合成方法
WO2017012773A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Solid forms of filgotinib free base
WO2017012771A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Crystalline filgotinib sulfonic acid addition salts
WO2017012770A1 (en) 2015-07-23 2017-01-26 Ratiopharm Gmbh Acid addition salts of filgotinib
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017106568A1 (en) * 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
WO2017106564A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017133423A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) 2016-03-01 2020-12-11 日商日本新藥股份有限公司 具jak抑制作用之化合物之結晶
CN105669669A (zh) * 2016-03-04 2016-06-15 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
WO2017162139A1 (zh) 2016-03-21 2017-09-28 苏州晶云药物科技有限公司 用于治疗或预防jak相关疾病药物的盐酸盐晶型及其制备方法
US10071079B2 (en) * 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3492468B1 (en) 2016-07-26 2022-02-23 Suzhou Longbiotech Pharmaceuticals Co., Ltd. Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
CN107759587B (zh) * 2016-08-19 2021-01-26 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
CN107880038B (zh) * 2016-09-30 2021-09-28 中国医药研究开发中心有限公司 [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039344B1 (ru) * 2017-01-19 2022-01-17 Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
JP7266576B2 (ja) 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
EP3710440B1 (en) 2017-11-14 2023-04-05 Bristol-Myers Squibb Company Substituted indole compounds
CA3085333A1 (en) 2017-12-15 2019-06-20 Bristol-Myers Squibb Company Substituted indole ether compounds
CN111819176B (zh) 2017-12-18 2023-12-15 百时美施贵宝公司 4-氮杂吲哚化合物
WO2019126113A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Substituted indole compounds useful as tlr inhibitors
MX2020005515A (es) 2017-12-19 2020-09-03 Bristol Myers Squibb Co Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
EA202091508A1 (ru) 2017-12-19 2020-09-14 Бристол-Маерс Сквибб Компани 6-азаиндольные соединения
BR112020012002A2 (pt) 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos diazaindol
ES2965182T3 (es) 2017-12-20 2024-04-11 Bristol Myers Squibb Co Compuestos de indol sustituidos con arilo y heteroarilo
BR112020011984A2 (pt) 2017-12-20 2020-11-17 Bristol-Myers Squibb Company compostos de amino indol úteis como inibidores de tlr
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US10815227B2 (en) 2018-08-27 2020-10-27 Cadila Healthcare Limited Processes for the preparation of filgotinib
KR102839382B1 (ko) 2018-10-24 2025-07-25 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 및 인다졸 화합물
WO2020086505A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
CN115029299B (zh) * 2018-11-07 2023-11-14 杭州瑞普晨创科技有限公司 JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) * 2019-03-05 2020-09-10 苏州科睿思制药有限公司 Filgotinib的马来酸盐晶型CSI及其制备方法和用途
JP7248256B2 (ja) 2019-03-14 2023-03-29 上海華匯拓医薬科技有限公司 Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
AU2020251400B2 (en) * 2019-03-30 2025-02-06 Unichem Laboratories Limited Novel process for the preparation of filgotinib and intermediates thereof
EP3965888B1 (en) 2019-05-09 2024-08-21 Bristol-Myers Squibb Company Substituted benzimidazolone compounds
CN110204542B (zh) * 2019-05-23 2022-05-20 四川伊诺达博医药科技有限公司 一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) * 2019-06-03 2019-08-23 上海基科生物化学有限公司 一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
JP7629007B2 (ja) 2019-10-01 2025-02-12 ブリストル－マイヤーズ スクイブ カンパニー 置換二環ヘテロアリール化合物
JP7545467B2 (ja) 2019-10-04 2024-09-04 ブリストル－マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
IT201900020240A1 (it) 2019-11-04 2021-05-04 Advitech Advisory And Tech Sa Procedimento per la preparazione di Filgotinib e intermedi di sintesi
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
CN110878097B (zh) * 2019-11-29 2021-11-02 杭州科巢生物科技有限公司 菲格替尼的制备方法
CN111072655B (zh) * 2019-12-30 2021-12-10 深圳市坤健创新药物研究院 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12419873B2 (en) 2020-02-13 2025-09-23 Zhuhai United Laboratories Co., Ltd. Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
AU2021222686B2 (en) 2020-02-21 2023-06-29 Zhuhai United Laboratories Co., Ltd. Crystalline form of JAK inhibitor and application thereof
WO2022039850A1 (en) * 2020-08-17 2022-02-24 Vyne Therapeutics Inc. Tofacitinib-containing anhydrous elastomer-based gel formulations
WO2022072238A1 (en) * 2020-10-02 2022-04-07 University Of Massachusetts Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) * 2021-05-19 2022-11-22 奥锐特药业(天津)有限公司 一种Filgotinib中间体的制备方法
CN113773322B (zh) * 2021-11-10 2022-02-11 奥锐特药业(天津)有限公司 一种Filgotinib的制备方法
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) * 2022-01-18 2023-07-28 盛世泰科生物医药技术(苏州)有限公司 一种含环丙酰胺化合物及其应用
WO2023194842A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in rheumatoid arthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ208996A (en) 1983-07-28 1989-08-29 American Cyanamid Co 5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
ES2228451T3 (es) 1999-01-29 2005-04-16 Chugai Seiyaku Kabushiki Kaisha Promotores de condrogenesis y derivados de indolin-2-ona.
WO2002087620A1 (en) 2001-04-27 2002-11-07 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
US6514989B1 (en) * 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
ES2264795T3 (es) 2003-02-14 2007-01-16 Pfizer Products Inc. Triazolo-piridinas como compuestos antiinflamatorios.
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
EP2360474B1 (en) 2004-06-21 2013-07-24 Galapagos N.V. Methods and means for treatment of osteoarthritis
CA2577478A1 (en) 2004-08-18 2006-02-23 Pharmacia & Upjohn Company Llc Triazolopyridine compounds
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
WO2008025821A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
PE20090370A1 (es) 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
MX2010000716A (es) 2007-07-18 2010-03-26 Novartis Ag Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
WO2009017954A1 (en) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CN101878212A (zh) 2007-08-31 2010-11-03 默克雪兰诺有限公司 三唑并吡啶化合物及其作为ask抑制剂的用途
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
US20100048557A1 (en) 2008-06-20 2010-02-25 Bing-Yan Zhu Triazolopyridine JAK Inhibitor Compounds and Methods
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
KR20120044966A (ko) 2009-06-05 2012-05-08 세파론, 인코포레이티드 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
UY34855A (es) 2012-06-22 2014-01-31 Galapagos Nv Aminotriazolopiridina para usar el tratamiento de la inflamación y composiciones farmacéuticas de ella.

Also Published As

Publication number Publication date
US8999979B2 (en) 2015-04-07
US11000528B2 (en) 2021-05-11
EA021637B1 (ru) 2015-07-30
AU2010264633A1 (en) 2011-12-22
PL3178819T3 (pl) 2020-04-30
US20120142678A1 (en) 2012-06-07
KR101850716B1 (ko) 2018-04-20
US20200078365A1 (en) 2020-03-12
CA2765985C (en) 2017-06-06
AU2017204744A1 (en) 2017-07-27
ME02699B (me) 2017-10-20
FR21C1011I2 (fr) 2022-03-25
JP2014221825A (ja) 2014-11-27
MX344951B (es) 2017-01-12
MA33448B1 (fr) 2012-07-03
US20180000831A1 (en) 2018-01-04
GB2483424A (en) 2012-03-07
HUS2100007I1 (hu) 2021-03-29
CR20120016A (es) 2012-02-09
ECSP12011626A (es) 2012-02-29
US9707237B2 (en) 2017-07-18
AU2015218544A1 (en) 2015-09-17
PT2445911T (pt) 2017-06-12
US20210369727A1 (en) 2021-12-02
US20100331319A1 (en) 2010-12-30
CN102482273B (zh) 2014-09-17
KR20180041262A (ko) 2018-04-23
WO2010149769A1 (en) 2010-12-29
DOP2011000388A (es) 2012-04-15
US20240325405A1 (en) 2024-10-03
DK3178819T3 (en) 2020-01-27
SMT201700265T1 (it) 2017-07-18
US8563545B2 (en) 2013-10-22
IL216667A0 (en) 2012-02-29
CN102482273A (zh) 2012-05-30
LTPA2021504I1 (lt) 2021-04-12
US9309244B2 (en) 2016-04-12
US8088764B2 (en) 2012-01-03
LTC2445911I2 (lt) 2022-09-26
TWI462920B (zh) 2014-12-01
ES2626908T3 (es) 2017-07-26
NL301096I1 (es) 2021-03-24
JP5591925B2 (ja) 2014-09-17
CL2011003247A1 (es) 2012-04-13
HRP20170826T1 (hr) 2017-08-25
KR20170007534A (ko) 2017-01-18
GB201200457D0 (en) 2012-02-22
CA2765985A1 (en) 2010-12-29
PE20121032A1 (es) 2012-08-25
HUE047478T2 (hu) 2020-04-28
HK1167403A1 (en) 2012-11-30
HRP20200033T1 (hr) 2020-03-20
EP3178819A1 (en) 2017-06-14
PL2445911T3 (pl) 2017-08-31
GB2483424B (en) 2012-07-18
SG177363A1 (en) 2012-02-28
LT3178819T (lt) 2020-01-27
NI201100222A (es) 2012-07-27
KR101916194B1 (ko) 2018-11-07
ES2766573T3 (es) 2020-06-12
DK2445911T3 (en) 2017-06-06
EP2445911B1 (en) 2017-03-01
AU2010264633B2 (en) 2015-06-04
MY156664A (en) 2016-03-15
KR20120107919A (ko) 2012-10-04
US20150274722A1 (en) 2015-10-01
PT3178819T (pt) 2020-01-21
EP3178819B1 (en) 2019-12-04
NO2021013I1 (no) 2021-03-23
AR077220A1 (es) 2011-08-10
AU2015218544B2 (en) 2017-04-27
EP2445911A1 (en) 2012-05-02
SI2445911T1 (sl) 2017-07-31
KR101696669B1 (ko) 2017-01-16
NZ596838A (en) 2014-01-31
ZA201109386B (en) 2012-08-29
BRPI1015569B8 (pt) 2021-05-25
US12042498B2 (en) 2024-07-23
NL301096I2 (nl) 2021-04-12
CN104262337A (zh) 2015-01-07
BRPI1015569B1 (pt) 2020-10-27
CY2021008I2 (el) 2021-06-25
US10328081B2 (en) 2019-06-25
CY2021008I1 (el) 2021-05-05
SG10201703497YA (en) 2017-06-29
FR21C1011I1 (es) 2021-05-07
EA201270075A1 (ru) 2012-12-28
SI3178819T1 (sl) 2020-02-28
MX2011013450A (es) 2012-05-08
BRPI1015569A2 (pt) 2016-08-16
US20140100220A1 (en) 2014-04-10
LT2445911T (lt) 2017-06-12
CY1122649T1 (el) 2021-03-12
TW201103936A (en) 2011-02-01
UA107935C2 (xx) 2015-03-10
RS56035B1 (sr) 2017-09-29
IL216667A (en) 2015-08-31
US20160296530A1 (en) 2016-10-13
CY1119214T1 (el) 2018-02-14
JP2012530766A (ja) 2012-12-06
HUE033154T2 (en) 2017-11-28

Similar Documents

Publication Publication Date Title
CO6491040A2 (es) 5-fenil-(1,2,4) triazolo (1,5-a) piridin - 2 il carboxamida como inhibidor de jak
UY32741A (es) ACIDO CICLOPROPANCARBOXÍLICO [1,2,4]TRIAZOL[1,5-a]PIRIDIN-2-IL-AMIDA UTILES PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y DEGENERATIVAS
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
PH12014502615B1 (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
MX2020003368A (es) Sal de acido maleico de {5-[4-(1,1-dioxo-tiomorfolin-4-ilmetil)-fe nil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida del acido ciclopropancarboxilico.
NZ722403A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
AR089960A1 (es) Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
UA105796C2 (uk) Сполука, застосовна для лікування дегенеративних і запальних захворювань

Legal Events

Date Code Title Description
FG Application granted